Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 4, 2026 · Other material event · Investor press release · Financial statements
Quoin Pharmaceuticals, Ltd.
7
Other material event
Jun 4, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Other material event · Investor press release · Financial statements |
| Primary topic | Other material event |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Quoin Pharmaceuticals, Ltd. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome -Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track Designation previously granted b… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 4, 2026 |
| Accession number | 0001104659-26-070501 |
| Reported items | Regulation FD disclosure (investor press release or presentation), Other events the company considers material, Financial statements and exhibits See Analysis tab for workforce implications |
